BRCA1 and neoplasm: Studies have shown that anti-angiogenesis drugs influence homologous recombination repair (HRR) through several mechanisms, such as inhibiting angiogenesis, inducing tumor hypoxia, and downregulating key HRR factors like BRCA1/2 and RAD51 (99).